Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL457553

CC[SiH](CC)CC.O=C(O)C(F)(F)F

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FAAH O00519 8/20 0.36
CES1 P23141 6/20 0.34
CES2 O00748 3/20 0.34
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.34
KMT2A Q03164 1/20 0.34
HSD17B10 Q99714 1/20 0.34
FFAR3 O14843 1/20 0.33
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32
FUCA1 P04066 1/20 0.32
EPHX1 P07099 1/20 0.31
ACLY P53396 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL5494627 0.97 FAAH (0.34) FAAHCES1CES2MEN1CYP1A2
Trifluoroacetic Acid SCHEMBL60804 0.93 FAAH (0.32) FAAHCES1CES2MEN1CYP1A2
Trifluoroacetic Acid SCHEMBL28246387 0.91 FAAH (0.31) FAAHCES1CES2MEN1CYP1A2
Trifluoroacetic Acid SCHEMBL8181430 0.89 DPP8 (0.32) FAAH
Trifluoroacetic Acid SCHEMBL27841664 0.82 FAAH (0.42) FAAHCES1CES2MEN1CYP1A2
Trifluoroacetic Acid SCHEMBL31031817 0.82 FAAH (0.42) FAAHCES1CES2MEN1CYP1A2
Trifluoroacetic Acid SCHEMBL3794549 0.79 FAAH (0.40) FAAHCES1CES2MEN1CYP1A2
Trifluoroacetic Acid SCHEMBL281599 0.79 FAAH (0.40) FAAHCES1CES2MEN1CYP1A2
Trifluoroacetic Acid SCHEMBL15711042 0.79 FAAH (0.46) FAAHCES1CES2MEN1CYP1A2
Trifluoroacetic Acid SCHEMBL30324569 0.79 FAAH (0.40) FAAHCES1CES2MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 379 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117820309-A Piperazinyl-heterocyclic compound and application thereof 江苏恩华药业股份有限公司 2024-04-05 CN claimed
CN-112154140-B Compound and application thereof in synthesizing Brivaracetam (Brivaracetam) bulk drug 福建海西新药创制股份有限公司 2023-11-24 CN claimed
CN-111961006-B Method for synthesizing intermediate of trilithiotinib triazole 同济大学 2023-03-28 CN claimed
CN-112279804-A Method for preparing 2-chloro-4-neopentyl pyridine 上海凌凯医药科技有限公司 2021-01-29 CN claimed
CN-112154140-A Compound and application thereof in synthesizing bulk drug of Brivaracetam (Brivaracetam) 福建海西新药创制有限公司 2020-12-29 CN claimed
CN-111961006-A Method for synthesizing intermediate of trilithiotinib triazole 同济大学 2020-11-20 CN claimed
WO-2020143674-A1 COMPOUNDS AND THEIR USE IN THE SYNTHESIS OF BRIVARACETAM APIS FUJIAN HAIXI PHARMACEUTICALS CO., LTD (CN) 2020-07-16 WO claimed
CN-105384619-B Isopropyl phenol derivative and preparation method thereof 四川海思科制药有限公司 2020-05-29 CN claimed
CN-105384607-B A kind of cumene amphyl and preparation method thereof 四川海思科制药有限公司 2019-08-16 CN claimed
CN-105384604-B A kind of cumene amphyl and preparation method thereof 四川海思科制药有限公司 2019-07-05 CN claimed
CN-107056730-B A kind of synthetic method and its application of bupropion hydrochloride sustained release tablets impurity isomers 浙江普洛家园药业有限公司 2019-05-24 CN claimed
EP-2282991-B1 METHOD FOR THE PRODUCTION OF 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES SANOFI AVENTIS DEUTSCHLAND (DE) 2018-01-24 EP claimed
US-8461312-B2 Method for the production of 1,4-benzothiepin-1,1-dioxide derivatives SANOFI (FR) 2013-06-11 US claimed
WO-2012147107-A2 NOVEL & IMPROVED PROCESSES FOR THE PREPARATION OF INDOLINE DERIVATIVES AND ITS PHARMACEUTICAL COMPOSITION MSN LABORATORIES LIMITED (IN) 2012-11-01 WO claimed
US-20110245486-A1 METHOD FOR THE PRODUCTION OF 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-10-06 US claimed
US-4535167-A CONDENSATION OF ACID AND ALDEHYDE FOLLOWED BY REDUCTIVE CLEAVAGE OF OXAZOLIDINONE INTERMEDIATE MERCK & CO. INC. (US) 1985-08-13 US claimed
EP-4630403-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2025-10-15 EP disclosed
WO-2024121129-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO disclosed
US-4448990-A Hydroxyaminotetralincarboxamides ELI LILLY AND COMPANY (US) 1984-05-15 US disclosed
US-4054740-A Hydroxybiotin HOFFMANN-LA ROCHE INC. (US) 1977-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245486-A1 METHOD FOR THE PRODUCTION OF 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES BBOX1, SULT1E1, PTGS1 FAAH 1416/4885CES1 205/4885CES2 1116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.